{
}
UBS has maintained a "Neutral" rating on Qiagen with a price target of $50. The company surpassed expectations for organic growth in the last quarter, and its adjusted operating profit margin was slightly above estimates. However, the growth forecast for the current quarter is below expectations, attributed to a gradual recovery in the consumer goods sector and ongoing investment challenges, though annual targets suggest an acceleration in future quarters.
UBS has upgraded Qiagen to a "Neutral" rating with a target price of $50, following the company's strong organic growth in the last quarter. Analyst Dan Leonard noted that while the adjusted operating profit margin exceeded expectations, the growth forecast for the current quarter is below estimates due to ongoing investment challenges. However, annual targets suggest a potential acceleration in growth in the upcoming quarters.
The global tuberculosis diagnostics market, valued at approximately $2.05 billion in 2023, is projected to grow to $3.6 billion by 2033, driven by advancements in nucleic acid testing and increasing healthcare investments. Key opportunities lie in smear microscopy, active tuberculosis detection, and hospital diagnostics, with significant growth expected in the Asia-Pacific and North America regions. Major players include Beckton, Dickinson and Company, Qiagen, and F. Hoffmann-La Roche, collectively holding a substantial market share.
The global clinical biomarkers market, valued at $25.02 billion in 2023, is projected to reach $47.25 billion by 2031, growing at a CAGR of 8.54%. This growth is driven by rising cancer cases and advancements in diagnostic technologies, despite challenges like high costs and reimbursement issues. Key players include Roche, Abbott, and Johnson & Johnson, with significant developments in biomarker testing for various diseases.
The global CRISPR and Cas gene market reached approximately $3.3 billion in 2023, growing at a CAGR of 20.38% since 2018. It is projected to expand to $8.8 billion by 2028 and $24.6 billion by 2033, driven by advancements in cancer therapeutics and gene therapy research. North America leads the market, accounting for 45.3% of the total value in 2023.
The Global Metagenomic Sequencing Market is projected to grow from US$ 1.41 billion in 2023 to US$ 4.39 billion by 2030, with a CAGR of 17.6%. Key factors driving this growth include increased demand, technological advancements, and a broadening customer base, alongside insights into competitive dynamics and market segmentation. Major players include Illumina, QIAGEN, and Thermo Fisher Scientific, with applications spanning drug discovery, disease diagnosis, and environmental remediation.
In January 2023, a significant acquisition occurred as Verinata Health, Inc. was purchased for $1.9 billion. The market for preterm birth diagnostic kits features key players like Qiagen and Hologic Inc., with products including ffN and PAMG-1 tests, serving hospitals and diagnostic labs across various global regions. The preterm birth prevention market is projected to grow from $1.70 billion in 2024 to over $4.49 billion by 2034, reflecting a robust CAGR of 10.2%.
UBS AG has maintained a "Neutral" rating on QIAGEN shares, setting a target price of $50. Analyst Dan Leonard noted mixed signals from the company's quarterly figures and outlook, leading to minor adjustments in his valuation model. As of the latest trading session, QIAGEN shares rose 0.3% to €40.89, reflecting a 0.7% gain since the start of 2024.
UBS has maintained a "Neutral" rating on Qiagen with a target price of 50 euros following the company's quarterly results, which surpassed expectations due to strong organic sales growth in diagnostics. However, the outlook for the biopharma sector indicates a slower recovery, and there are doubts about Qiagen's ability to match competitors' growth rates.
QIAGEN NV, a Netherlands-based holding company, specializes in "Sample to Insight" solutions that convert biological samples into molecular knowledge. Their technologies encompass sampling, analysis, bioinformatics, and automation systems, enabling the isolation and preparation of DNA, RNA, and proteins for various applications, including genetic analysis. The integration of these elements supports comprehensive molecular testing workflows.
Qiagen N.V.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
UBS maintains neutral stance on Qiagen with 50 dollar price target
08:34 06.02.2025
ubs upgrades qiagen to neutral with target price of 50 dollars
07:34 06.02.2025
growth opportunities in the tuberculosis diagnostics market through 2033
Euro
United States Dollar
Bio-Techne Corporation
Thermo Fisher Scientific Inc.
Qiagen N.V.
Bio-Rad Laboratories, Inc.
PerkinElmer Inc
Becton, Dickinson and Company
BioMerieux SA
Abbott Laboratories
USA
Show more
10:21 06.01.2025
global clinical biomarkers market projected to reach 47 billion by 2031
Eurofins Scientific S.E. A
PerkinElmer Inc
Johnson & Johnson Services Inc.
Bio-Rad Laboratories, Inc.
Qiagen N.V.
Merck KGaA
Thermo Fisher Scientific Inc.
General Electric Co
Siemens Healthineers AG
Agilent Technologies, Inc.
F. Hoffmann-La Roche Ltd.
USA
Show more
08:45 16.12.2024
global growth trends in the crispr and cas gene market to 2033
United States Dollar
Bayer AG
Bio-Rad Laboratories, Inc.
Pluristem Therapeutics Inc.
Genscript Biotech Corporation
AstraZeneca PLC
Qiagen N.V.
Hologic, Inc.
Cellectis S.A.
Takara Bio Inc.
Vertex Pharmaceuticals Inc
Thermo Fisher Scientific Inc.
Sigma-Aldrich Co. LLC
Regeneron Pharmaceuticals Inc
Editas Medicine Inc
IND
GBR
ESP
CAN
AUS
ITA
IDN
JPN
BRA
DEU
FRA
RUS
KOR
CHN
USA
Show more
15:27 13.12.2024
global metagenomic sequencing market poised for significant growth by 2030
United States Dollar
BGI Group
GENEWIZ
Novogene Corporation
Eurofins Scientific SE
PerkinElmer
Macrogen
Zymo Research
Nugen Technologies Inc.
Takara Bio Inc.
Swift Biosciences
Thermo Fisher Scientific Inc.
BaseClear
MR DNA (Molecular Research)
Diversigen
CosmosID
Oxford Nanopore Technologies
NEW England Biolabs Inc.
Illumina, Inc.
Qiagen N.V.
Microsynth AG
Priya Pandey
Viju Shah
Show more
11:59 26.11.2024
global healthcare market trends forecast significant growth through 2034
United States Dollar
Illumina, Inc.
Bio-Rad Laboratories, Inc.
Nanjing Liming Biological Preparations Co., Ltd.
Qiagen N.V.
Hologic, Inc.
USA
Bio-Rad Laboratories
Invitae
Sabyasachi Ghosh
Illumina Inc.
Natera Inc.
Show more
15:31 13.11.2024
qiagen shares rated neutral by ubs with target price of 50 dollars
12:34 11.11.2024
UBS maintains neutral rating on Qiagen with target price of 50 euros
08:20 07.11.2024
qiagen nv enhances molecular testing with integrated sample to insight solutions
08:08 07.11.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Retail and Consumer Goods
Stock Market Updates
Supply Chain Management
Industry Mergers & Acquisitions
Government Economic Policies
Fintech Startups
Private Equity Deals
CEO Changes
Venture Capital Investments
AI Applications
Corporate Social Responsibility
AI Innovations
Funding Rounds & Investments
Economic Indicators
Market Analysis and Predictions
Emerging Startups
Countries:
Companies:
Apple Inc.
Google Inc.
OLA ELECTRIC MOBILITY LTD
NVIDIA Corp
Grab2Go AS
Amazon.com, Inc.
Microsoft Corporation
EFG Hermes Egypt
Broadcom Inc.
Tesla, Inc.
Delhivery Limited
Ecom Express Ltd.
Scripbox.COM India Ltd.
SK hynix Inc.
Tesmec S.p.A.
OpenAI ERC USD
FTSE NASDAQ Dubai UAE 20 Index
The Goldman Sachs Group, Inc.
Microsoft Corp
JPMorgan Chase & Co.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Japanese Yen
Euro
South Korean Won
Pakistani Rupee
Egyptian Pound
United Arab Emirates Dirham
Brazilian Real
Qatari Riyal
Saudi Riyal
Indonesian Rupiah
Vietnamese Đồng
Hong Kong Dollar
Offshore Chinese Yuan
Canadian Dollar
Malaysian Ringgit
People: